Selank is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-03-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.
Once dissolved, the peptide is markedly less stable than the dry powder. Aqueous solutions are subject to backbone hydrolysis and to microbial growth when they are handled without sterile technique. Buffered solutions near neutral pH are common for short-term laboratory work, while acidic conditions are sometimes used to improve solubility. Analytical laboratories generally prepare working solutions fresh rather than storing them, and a residual water film left in a reopened vial can seed degradation even when the container appears dry.
Reversed-phase high-performance liquid chromatography is the standard technique for estimating peptide purity. The result is a peak-area percentage, which describes how much of the detected material elutes as the main peak in one run. Mass spectrometry confirms the molecular mass and can reveal truncated, adducted, or otherwise modified species. Amino acid analysis or tandem mass spectrometry can address sequence fidelity when identity is in doubt. None of these measurements, taken alone, establishes that a sample is fit for any specific purpose.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Analog of the tetrapeptide tuftsin |
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Reported consistently across pharmacopoeial descriptions |
| Appearance | White to off-white lyophilized powder | Typical form of research-grade material |
| Solubility | Freely soluble in water | Aqueous buffers; poor in nonpolar solvents |
| Typical storage temperature | -20 degrees Celsius | Lyophilized powder; protect from moisture |
Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres is the standard purity method. Mass spectrometry, typically electrospray ionisation, confirms identity through the expected mass-to-charge pattern. Amino acid analysis can verify composition independently. Chiral purity requires separate techniques such as derivatisation followed by chromatographic separation, and such data are rarely reported for research-grade material.
Quantification in biological matrices relies on liquid chromatography coupled to tandem mass spectrometry with stable-isotope internal standards. Low plasma concentrations and adsorption to container surfaces both complicate measurement. Solid-phase extraction is often needed to reduce matrix interference before injection. Reported limits of quantification differ widely between laboratories, which makes direct comparison of pharmacokinetic results difficult and limits meta-analysis.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
=== Dosage === When used to treat SVT, adenosine is administered intravenously as a rapid bolus (typically 0.10–0.15 mg/kg initially) over 1-2 seconds, followed by a rapid saline flush (often using a 2-way or 3-way stopcock). If the initial dose is ineffective, it may be repeated every 2 minutes with a slightly increased dose (0.05–0.1 mg/kg increments) every 2 minutes up to a maximum total dose of 0.3 mg/kg (not exceeding 12 mg). Due to adenosine's extremely short half-life (less than 10 seconds), it is often injected through a central venous line or a large proximal peripheral vein; administration into lower extremities, PICC lines, or smaller veins may lead to therapeutic failure due to rapid metabolism before reaching the heart. When given to dilate the arteries, such as in a "stress test", the dosage is typically 0.14 mg/kg/min, administered for 4 or 6 minutes, depending on the protocol. The recommended dose may be increased in patients on theophylline since methylxanthines prevent binding of adenosine at receptor sites. The dose is often decreased in patients on dipyridamole (Persantine) and diazepam (Valium) because adenosine potentiates the effects of these drugs. The recommended dose is also reduced by half in patients presenting congestive heart failure, myocardial infarction, shock, hypoxia, and/or chronic liver disease or chronic kidney disease, and in elderly patients.
=== Monoclonal antibodies targeting the CGRP molecule === Eptinezumab (ALD403) is approved for prevention of migraine. Fremanezumab (TEV-48125) is approved for prevention of migraine. Galcanezumab (LY2951742) is approved for prevention of migraine and cluster headaches.
==== Symptoms ==== Necrosis may be symptomatic or asymptomatic. Symptomatic necrosis involves lingering pain response to hot and cold stimuli, spontaneous pain that may cause a patient to awaken during sleep, difficulty eating and sensitivity to percussion. Asymptomatic necrosis is non-responsive to thermal stimuli or electric pulp tests, leaving the patient unaware of the pathology.
=== Bibliography === "Annex A – Estate Baseline – 2009" (PDF). Defence Estates Development Plan (DEDP) 2009. GOV.UK (Report). Ministry of Defence. 3 July 2009. Retrieved 30 March 2023. Halley, James J (1988). RAF Squadrons. The Squadrons of the Royal Air Force & Commonwealth 1918–1988. Tonbridge, UK: Air Britain (Historians). ISBN 0-85130-164-9. Jackson, Paul (1986). Britain's Armed Forces Today: 4 RAF Germany. Shepperton, UK: Ian Allan. ISBN 0-7110-1579-1. Jefford, C. G. (1988). RAF Squadrons. A comprehensive record of the movement and equipment of all RAF squadrons and their antecedents since 1912. Shrewsbury, UK: Airlife. ISBN 1-85310-053-6. Langford, F. (1991). The Dorset Year Book - 1991. Dorset, UK: The Society Of Dorset Men. March, Peter R. (1992). Royal Air Force Yearbook 1992. Fairford, UK: Royal Air Force Benevolent Fund. March, Peter R. (1998). Royal Air Force Yearbook 1998. Fairford, UK: Royal Air Force Benevolent Fund. Sturtivant, Ray; Hamlin, John (2007). Royal Air Force flying training and support units since 1912. Tonbridge, UK: Air-Britain (Historians). ISBN 978-0851-3036-59.
Sources: en.wikipedia.org
Icalcaprant (developmental code name CVL-354) is a κ-opioid receptor (KOR) antagonist which is under development for the treatment of major depressive disorder and substance-related disorders. It is taken by mouth. It acts as a selective antagonist of the KOR. The drug is also more weakly an antagonist of the μ-opioid receptor (MOR), with about 31-fold lower affinity and 27-fold lower inhibitory potency at the MOR relative to the KOR. It was originated by Pfizer and is under development by Cerevel Therapeutics (a subsidiary of AbbVie). As of September 2022, icalcaprant is in phase 1 clinical trials for major depressive disorder and is in the preclincal stage of development for substance-related disorders.
==== Mechanism of action ==== A photosensitizer generates ROS through one of two processes. Type I involves a redox reaction that results in the creation of superoxides (O2•−), hydroxyl radicals (OH•), and radical peroxides, whereas Type II generates singlet oxygen directly through an electron transfer from the photosensitizer. These ROS go on to nonspecifically damage a variety of cellular components, including proteins, DNA, and lipids as they seek to remove the radical.
=== Businesses === Air Link, New South Wales, Australia Hong Kong Link, toll tunnels and bridges company Link REIT, Hong Kong real estate investment trust The Link (retailer), UK mobile phone retailer Link Aviation Devices, a manufacturer of aircraft simulator, now a subsidiary of L3 Technologies
CA7 is a small-molecule oxytocin receptor agonist. It is said to be potent as an agonist of the oxytocin receptor and to show considerable selectivity over the vasopressin V1A receptor, where it displayed no functional activity. However, the exact affinity and activity values at these receptors do not appear to have been disclosed. The chemical synthesis of CA7 has been described. Along with its close analogue WJ0679, CA7 has the smallest chemical structure known for an oxytocin receptor agonist, with WJ0679 having about 60% of the molecular weight of LIT-001 and both WJ0679 and CA7 lacking LIT-001's tail component. Many analogues of WJ0679 and CA7 have been described. CA7 was first described in the scientific literature by a group including Michael Kassiou, Michael Bowen, Iain McGregor, and others at the University of Sydney in 2018. This group has founded a startup pharmaceutical company called Kinoxis Therapeutics and is developing small-molecule oxytocin-related drugs like KNX-100 and the KNX-200 series for potential medical use as of the 2020s.
=== Use in drug-induced neutropenia === Neutropenia can be a severe side effect of clozapine, an antipsychotic medication in the treatment of schizophrenia. G-CSF can restore neutrophil count. Following a return to baseline after stopping the drug, it may sometimes be safely rechallenged with the added use of G-CSF.
Sources: en.wikipedia.org
== Bibliography == Antoni Czubiński, Powstanie Wielkopolskie 1918–1919. Geneza-charakter-znaczenie, Poznań 1978 Antoni Czubiński, Rola Powstania Wielkopolskiego w walce narodu polskiego o powstrzymanie niemieckiego >parcia na wschód<, Przegląd Zachodni 1968, nr 5–6 A. Czubiński, Z.Grot, B.Miśkiiewcz, Powstanie Wielkopolskie 1918–1919. Zarys dziejów, Warszawa 1978 K. Dembski, Wielkopolska w początkach II Rzeczypospolitej. Zagadnienia prawno-ustrojowe, Poznań 1972 Roman Dmowski, Polityka polska i odbudowanie państwa 1925 Z. Grot (ed.), Powstanie wielkopolskie 1918–1919, Poznań 1968 Z. Grot, I. Pawłowski, M. Pirko, Wielkopolska w walce o niepodległość 1918–1919. Wojskowe i polityczne aspekty Powstania Wielkopolskiego, Warszawa 1968 P. Hauser, Niemcy wobec sprawy polskiej X 1918–VI 1919, Poznań 1984 K. Kandziora, Działalność POW w Poznaniu. Przyczynek do historii Polskiej Organizacji Wojskowej zaboru pruskiego w latach 1918–1919, Warszawa 1939 S. Kubiak, Niemcy a Wielkopolska 1918–1919, Poznań 1969 Joseph Lamia: Der Aufstand in Posen (The Uprising in Poznan). Berlin 1919 (in German). Materiały Sesji Naukowej z okazji 50-lecia Powstania Wielkopolskiego 1918/1919, Zaszyty Naukowe UAM 1970, Historia t.10 Witold Mazurczak, Anglicy i wybuch powstania wielkopolskiego. Z dziejów genezy brytyjskiej misji płka H.H.Wade'a w Polsce, [in:] Antoni Czubiński (ed.), Polacy i Niemcy. Dziesięć wieków sąsiedztwa, PWN, Warszawa 1987 Janusz Pajewski, Rodział XXII.
== Treatment == No specific cure has been discovered for homocystinuria; however, many people are treated using high doses of vitamin B6 (also known as pyridoxine). Slightly less than 50% respond to this treatment and need to take supplemental vitamin B6 for the rest of their lives. Those who do not respond usually respond to supplementation with folic acid and trimethylglycine (betaine). Typically this is mediated by cystathionine beta-synthase activity, i.e. those who have adequate CBS activity typically respond to B6 . Occasionally adding cysteineto the diet can be helpful, as glutathione is synthesized from cysteine (so adding cysteine can be important to reduce oxidative stress). Riboflavin, a cofactor for the MTHFR enzyme pathway and multiple glutathione-related pathways, may also be used. Betaine (N,N,N-trimethylglycine) is used to reduce concentrations of homocysteine by promoting the conversion of homocysteine back to methionine, i.e., increasing flux through the re-methylation pathway independent of folate derivatives (which is mainly active in the liver and in the kidneys). The re-formed methionine is then gradually removed by incorporation into body protein. The methionine that is not converted into protein is converted to S-adenosyl-methionine which goes on to form homocysteine again. Betaine is, therefore, only effective if the quantity of methionine to be removed is small. Hence treatment includes both betaine and a diet low in methionine.
In bacteria and organelles, the initiation of protein synthesis is signaled by the formation of formyl-methionyl-tRNA (tRNAfMet). This reaction is dependent on 10-formyltetrahydrofolate, and the enzyme methionyl-tRNA formyltransferase. This reaction is not used by eukaryotes or Archaea, as the presence of tRNAfMet in non bacterial cells is dubbed as intrusive material and quickly eliminated. After its production, tRNAfMet is delivered to the 30S subunit of the ribosome in order to start protein synthesis. fMet possesses the same codon sequence as methionine. However, fMet is only used for the initiation of protein synthesis and is thus found only at the N terminus of the protein. Methionine is used during the rest translation. In E. coli, tRNAfMet is specifically recognized by initiation factor IF-2, as the formyl group blocks peptide bond formation at the N-terminus of methionine. Once protein synthesis is accomplished, the formyl group on methionine can be removed by peptide deformylase. The methionine residue can be further removed by the enzyme methionine aminopeptidase.
== Definition == There is ongoing debate over how cyberwarfare should be defined and no absolute definition is widely agreed upon. While the majority of scholars, militaries, and governments use definitions that refer to state and state-sponsored actors, other definitions may include non-state actors, such as terrorist groups, companies, political or ideological extremist groups, hacktivists, and transnational criminal organizations depending on the context of the work. Examples of definitions proposed by experts in the field are as follows.
=== Daria Greenock === Daria Greenock (Freya Mavor) is a VP at Pierpoint's CPS desk, and Harper's line manager during her internship. Daria works to foster a poised, professional relationship with Harper, who nonetheless finds herself drawn more to Eric's fiery, cutthroat management style, frequently undercutting Daria in the process. When Harper confides to Daria that Eric locked her in a conference room to berate her for a mistake, Daria tells Sara and the two push Harper to file a formal complaint, getting Eric fired and positioning Daria to become CPS' managing director in his place. Harper is initially allowed to keep the outsize bonus that Eric paid her as long as she keeps it quiet, but Daria later has Harper pay it back after Harper talks about it during a party. On RIF day, Harper accepts a deal to retract her complaint against Eric and get him rehired, leading to Daria's firing. In series 2, Daria is revealed to have joined Goldman Sachs; though she is on maternity leave, she visits the office during a sham interview with Harper, Eric, and Rishi to revel in their humiliation. In series 3, however, Daria agrees to help Harper short Pierpoint alongside Kenny and Jackie, who have also joined Goldman Sachs, out of spite towards their ex-employer.
Sources: en.wikipedia.org
Selank is a synthetic seven-amino-acid peptide modeled on tuftsin, a fragment of the immunoglobulin G heavy chain. It was designed in Russia to combine anxiolytic and immunomodulatory properties in one molecule.
The first four residues of Selank reproduce the tuftsin sequence Thr-Lys-Pro-Arg. A Pro-Gly-Pro extension at the C-terminus was added to slow enzymatic breakdown and extend residence time.
It holds marketing authorization in Russia, where nasal drop formulations are sold. No equivalent approval exists in the European Union, the United States, or most other countries.
Sealed, desiccated storage at -20 °C or colder is the standard recommendation for research-grade material. Vials should reach room temperature before they are opened, which limits condensation. Repeated temperature cycling is discouraged.